We assessed the effects of androgen on ELK1 expression by reverse transcription (RT)-polymerase chain reaction (PCR), western blotting, and immunofluorescence in bladder cancer cells treated with DHT and/or an AR antagonist hydroxyflutamide (HF). This evidence concerns the gene ELK1 and urinary bladder carcinoma.